Renal cell carcinoma: mTOR as a target for therapy of renal

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 10, 2007, Pages 772-774

  Hudes, Gary R ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b Genitourinary Malignancies Program

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEVAXAR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; PROTEIN KINASE;

ANEMIA; ANGIOGENESIS; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; MONOTHERAPY; NAUSEA; PERIPHERAL EDEMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METHODOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PROTEIN KINASES;

EID: 38749111823     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Arkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
2. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007; 13(2 pt 2):758s-763s.
3. Cho D, Signoretti S, Regan M, et al. Low expression of surrogates for-mTOR pathway activation predict for resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC). Presented at AACR-NCI-EORTC International Conference on Molocular Therapeutics. November 14-18, 2005; Philadelphia, Penn.
4. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
5. Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol. 2007;25(18S pt 1): Abstract 5107.
6. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23: 832-841.
7. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25: 3958-3964.
8. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267.
9. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336-2347.
10. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 2007; 177:346-352.